Kiniksa Pharmaceuticals (KNSA) Competitors $21.36 +0.80 (+3.89%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$24.00 +2.64 (+12.36%) As of 04/25/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. TGTX, TLX, BPMC, SRPT, AXSM, NUVL, VRNA, GRFS, KRYS, and ADMAShould you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Verona Pharma (VRNA), Grifols (GRFS), Krystal Biotech (KRYS), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals vs. TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Nuvalent Verona Pharma Grifols Krystal Biotech ADMA Biologics Kiniksa Pharmaceuticals (NASDAQ:KNSA) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Which has more risk and volatility, KNSA or TGTX? Kiniksa Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Is KNSA or TGTX more profitable? Kiniksa Pharmaceuticals has a net margin of -2.36% compared to TG Therapeutics' net margin of -5.42%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals-2.36% -7.31% -5.95% TG Therapeutics -5.42%-8.32%-3.40% Does the media favor KNSA or TGTX? In the previous week, TG Therapeutics had 8 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 13 mentions for TG Therapeutics and 5 mentions for Kiniksa Pharmaceuticals. TG Therapeutics' average media sentiment score of 1.66 beat Kiniksa Pharmaceuticals' score of 0.58 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals & insiders have more ownership in KNSA or TGTX? 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, KNSA or TGTX? Kiniksa Pharmaceuticals has higher revenue and earnings than TG Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals$423.24M3.67$14.08M-$0.61-35.02TG Therapeutics$329.00M19.95$12.67M$0.14295.21 Do analysts rate KNSA or TGTX? Kiniksa Pharmaceuticals presently has a consensus price target of $37.17, indicating a potential upside of 74.00%. TG Therapeutics has a consensus price target of $40.67, indicating a potential downside of 1.60%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the MarketBeat Community believe in KNSA or TGTX? TG Therapeutics received 485 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 65.41% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKiniksa PharmaceuticalsOutperform Votes17465.41% Underperform Votes9234.59% TG TherapeuticsOutperform Votes65976.27% Underperform Votes20523.73% SummaryKiniksa Pharmaceuticals and TG Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.55B$6.70B$5.47B$7.82BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-152.567.2022.3718.43Price / Sales3.67239.17391.12101.46Price / CashN/A65.8538.1834.62Price / Book3.436.306.684.19Net Income$14.08M$142.95M$3.22B$248.05M7 Day Performance5.69%8.00%6.24%6.53%1 Month Performance-6.15%-4.16%-2.82%-2.16%1 Year Performance19.46%-2.77%16.46%4.71% Kiniksa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals2.2384 of 5 stars$21.36+3.9%$37.17+74.0%+21.3%$1.55B$423.24M-152.56220Insider TradeTGTXTG Therapeutics3.294 of 5 stars$36.97-3.5%$40.67+10.0%+197.1%$5.81B$329.00M-369.66290Upcoming EarningsNews CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/ABPMCBlueprint Medicines2.3093 of 5 stars$84.18-0.6%$124.95+48.4%-3.4%$5.38B$508.82M-77.94640Upcoming EarningsNews CoveragePositive NewsSRPTSarepta Therapeutics4.6604 of 5 stars$55.23+2.7%$158.70+187.3%-52.6%$5.36B$1.90B44.18840Upcoming EarningsAXSMAxsome Therapeutics4.7804 of 5 stars$103.00-1.4%$169.80+64.9%+48.6%$5.02B$385.69M-17.20380Short Interest ↓Positive NewsNUVLNuvalent1.8489 of 5 stars$69.95-2.4%$115.50+65.1%+11.2%$5.01BN/A-20.1640News CoveragePositive NewsVRNAVerona Pharma1.8587 of 5 stars$60.07+2.0%$75.43+25.6%+327.6%$4.85B$42.28M-31.2930Upcoming EarningsShort Interest ↓Analyst RevisionNews CoveragePositive NewsGRFSGrifols3.8519 of 5 stars$7.01-1.0%N/A+15.0%$4.82B$7.21B5.9926,300Short Interest ↓Gap UpKRYSKrystal Biotech4.8797 of 5 stars$161.91-4.0%$220.00+35.9%+8.0%$4.68B$290.52M54.15210News CoveragePositive NewsADMAADMA Biologics1.4546 of 5 stars$19.64-7.8%$22.50+14.6%+239.4%$4.64B$426.45M70.14530Positive News Related Companies and Tools Related Companies TG Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Blueprint Medicines Alternatives Sarepta Therapeutics Alternatives Axsome Therapeutics Alternatives Nuvalent Alternatives Verona Pharma Alternatives Grifols Alternatives Krystal Biotech Alternatives ADMA Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KNSA Stock Free KNSA Stock Alerts